secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2025-03-13T23:59:59+00:00
Accession:  0001517022-25-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia Q4 net loss $22.8M; expects Vafseo Q1 2025 revenue ~$10-11M
------------------------------------------------------------------

- Total revenues Q4 $46.5M, down 17% YoY; Auryxia net revenue $44.4M vs $53.2M.
- Net loss Q4 $22.8M vs net income $0.6M; FY2024 net loss $69.4M vs $51.9M.
- Vafseo launch: shipments began Jan 9; >500 prescribers through Feb; Q1 revenue guidance $10-11M.
- Cash $51.9M at Dec 31; post-year-end raised $18.4M ATM + $9.3M BlackRock; funded ≥2 years.
- Plan to initiate Phase 3 VALOR trial for vadadustat in non-dialysis CKD in H2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/0001517022-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702225000017/akba-20250313.htm
  HTML page:      https://secwatch.observer/filing/0001517022-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer